Artelo Biosciences Inc ARTL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/26/24 EDT
1.31quote price arrow down-0.03 (-2.23%)
Volume
3,009,265
Close
1.34UNCH (UNCH)
Volume
5,726
52 week range
1.15 - 2.98
Loading...
  • Open1.36
  • Day High1.36
  • Day Low1.31
  • Prev Close1.34
  • 52 Week High2.98
  • 52 Week High Date09/07/23
  • 52 Week Low1.15
  • 52 Week Low Date11/20/23

Key Stats

  • Market Cap4.325M
  • Shares Out3.23M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.48
  • YTD % Change-4.29

KEY STATS

  • Open1.36
  • Day High1.36
  • Day Low1.31
  • Prev Close1.34
  • 52 Week High2.98
  • 52 Week High Date09/07/23
  • 52 Week Low1.15
  • 52 Week Low Date11/20/23
  • Market Cap4.325M
  • Shares Out3.23M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.48
  • YTD % Change-4.29

RATIOS/PROFITABILITY

  • EPS (TTM)-3.12
  • P/E (TTM)-0.43
  • Fwd P/E (NTM)-0.46
  • EBITDA (TTM)-9.93M
  • ROE (TTM)-59.63%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Artelo Biosciences Inc

 

Profile

MORE
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled...
Connie Matsui
Independent Chairman of the Board
Gregory Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary, Director
Address
505 LOMAS SANTA FE, SUITE 160
Solana Beach, CA
92075
United States